Loading stock data…
PMVP
$1.05-0.04 (-3.67%)
After Hours$1.05+0.00 (+0.00%)· Last close Jun 9
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PMV Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.05. Wall Street consensus targets $4.33 (3 analysts), implying a +312.7% move over the next 12 months. The stock is currently near its 52-week low of $0.96, remaining 20.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +312.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 18) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.05
Potential Downside
0%
Whystock Fair Value$1.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-89.06%
Volume
Today's trading volume
225,312
Recent News
Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) is among the most popular penny stocks on Robinhood. TheFly reported on May 13 that Oppenheimer reduced its price target on PMVP from $6 to $5 while maintaining an Outperform rating after the company’s […]
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Staar Surgical (NASDAQ:STAA) shares rose 15.3% to $33.9 during Wednesday's after-market session. The company's market cap stands at $1.3 billion. As per the press release, Q1 earnings came out today. Precision Optics Corp (NASDAQ:POCI) shares moved upwards by 15.21% to $5.3. The market value of their outstanding shares is at $49.6 million. As per the news, the Q3 earnings report came out today. Aquestive Therapeutics (NASDAQ:AQST) stock moved upwards by 13.55% to $4.69. The market value
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.